Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities.
about
CD147 silencing inhibits tumor growth by suppressing glucose transport in melanoma.Integrating functional genomics to accelerate mechanistic personalized medicine.Functional precision cancer medicine-moving beyond pure genomics.Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A
P2860
Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Parallel In Vivo Assessment of ...... red Treatment Vulnerabilities.
@en
Parallel In Vivo Assessment of ...... red Treatment Vulnerabilities.
@nl
type
label
Parallel In Vivo Assessment of ...... red Treatment Vulnerabilities.
@en
Parallel In Vivo Assessment of ...... red Treatment Vulnerabilities.
@nl
prefLabel
Parallel In Vivo Assessment of ...... red Treatment Vulnerabilities.
@en
Parallel In Vivo Assessment of ...... red Treatment Vulnerabilities.
@nl
P2093
P2860
P1476
Parallel In Vivo Assessment of ...... ered Treatment Vulnerabilities
@en
P2093
Frank B Gertler
Keith T Flaherty
Michael J Cima
Oliver Jonas
Robert Langer
Tatsiana Kosciuk
P2860
P304
P356
10.1158/1078-0432.CCR-15-2722
P407
P577
2016-04-18T00:00:00Z